CAR T and Bispecific Agents in Hematologic Malignancies

Expert perspectives and strategic insights on new and relevant clinical advances of CAR T and bispecific agents in hematologic malignancies

September 7 and 15, 2021

Faculty Chair

Elias Jabbour, MD

The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Faculty Members

Ibrahim Aldoss, MD
City of Hope, Duarte, CA

Sattva Neelapu, MD
MD Anderson Cancer Center, Houston, TX

Krina Patel, MD
MD Anderson Cancer Center, Houston, TX

Krishna Komanduri, MD
Sylvester Comprehensive Cancer Center, Miami, FL

Julio Chavez, MD
H Lee Moffitt Cancer Center, Tampa, FL

Jae Park, MD
Memorial Sloan Kettering Cancer Center, New York, NY

Sagar Lonial, MD, FACP
Winship Cancer Institute of Emory University, Atlanta, GA

Noopur Raje, MD
Mass General Cancer Center, Boston, MA

Sample Report

Start discovering the insights

View Report


  • CAR T Cells in Leukemias (including ALL/AML)
  • CAR T Cells in DLBCL
  • CAR T Cells in MCL and FL
  • CAR T Cells in MM
  • Bispecific Agents in Leukemias
  • Bispecific Agents in B-NHL
  • Bispecific Agents in Myeloma
  • Managing Toxicity of Bispecific Agents and CAR T Cells

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.